Introduction

Molecular Medicine Reports

1791-2997 1791-3004

D.A. Spandidos

10.3892/mmr.2020.11310

mmr-22-03-2199

Articles

Downregulation of miR-193a-3p via targeting cyclin D1 in thyroid cancer

Xiao-Jiao

1 * Wen

Rong

2 * Wen

Dong-Yue

2 Lin

Peng

2 Pan

Deng-Hua

2 Zhang

Li-Jie

2 He

2 Shi

Lin

3 Qin

Yong-Ying

2 Lai

Yun-Hui

3 Lai

Jing-Ni

2 Yang

Jun-Lin

2 Lai

Qin-Qiao

3 Wang

Jun

3 Ma

Jun

3 Yang

Hong

2 Pang

Yu-Yan

1Department of Positron Emission Tomography-Computed Tomography (PET-CT), First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China 2Ultrasonics Division of Radiology Department, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China 3Department of Pathology, Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530007, P.R. China 4Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China

Correspondence to: Professor Hong Yang, Ultrasonics Division of Radiology Department, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China, E-mail: yanghong@gxmu.edu.cn Professor Yu-Yan Pang, Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China, E-mail: hornor159@126.com *

Contributed equally

092020

08072020

22 3 2199 2218 04052019 09042020

2020

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Thyroid cancer (TC) is a frequently occurring malignant tumor with a rising steadily incidence. microRNA (miRNA/miR)-193a-3p is an miRNA that is associated with tumors, playing a crucial role in the genesis and progression of various cancers. However, the expression levels of miR-193a-3p and its molecular mechanisms in TC remain to be elucidated. The present study aimed to probe the expression of miR-193a-3p and its clinical significance in TC, including its underlying molecular mechanisms. Microarray and RNA sequencing data gathered from three major databases, specifically Gene Expression Omnibus (GEO), ArrayExpress and The Cancer Genome Atlas (TCGA) databases, and the relevant data from the literature were used to examine miR-193a-3p expression. Meta-analysis was also conducted to evaluate the association between clinicopathological parameters and miR-193a-3p in 510 TC and 59 normal samples from the TCGA database. miRWalk 3.0, and the TCGA and GEO databases were used to predict the candidate target genes of miR-193a-3p. Gene Ontology, Kyoto Encyclopedia of Genes and Genomes and protein-protein interaction network enrichment analyses were conducted by using the predicted candidate target genes to investigate the underlying carcinogenic mechanisms. A dual luciferase assay was performed to validate the targeting regulatory association between the most important hub gene cyclin D1 (CCND1) and miR-193a-3p. miR-193a-3p expression was considerably downregulated in TC compared with in the non-cancer controls (P<0.001). The area under the curve of the summary receiver operating characteristic was 0.80. Downregulation of miR-193a-3p was also significantly associated with age, sex and metastasis (P=0.020, 0.044 and 0.048, respectively). Bioinformatics analysis indicated that a low miR-193a-3p expression may augment CCND1 expression to affect the biological processes of TC. In addition, CCND1, as a straightforward target, was validated through a dual luciferase assay. miR-193a-3p and CCND1 may serve as prognostic biomarkers of TC. Finally, miR-193a-3p may possess a crucial role in the genesis and progression of TC by altering the CCND1 expression.

thyroid cancer microRNA-193a-3p cyclin D1 in-house dual luciferase assay meta-analysis

Introduction

Thyroid cancer (TC) is a frequently occurring malignant tumor with steadily increasing incidence (1–5). In 2018, the American Cancer Society predicted that there would be 53,990 newly diagnosed patients with TC that year (6). Based on histopathological examination, TC is divided into 4 subtypes: Anaplastic thyroid carcinoma, papillary thyroid carcinoma, medullary thyroid cancer and follicular thyroid cancer (7–9). Different hypotypes of TC lead to various clinical outcomes. A number of studies have reported that intricate biological processes participating in the interactions between polygenes may contribute to the occurrence and progression of TC (10–12). Previous studies have suggested that hsa-miR-200a-5p and hsa-miR-181a-2-3p could be applied for latent diagnostic and prognostic biomarkers of TC (13,14). Nevertheless, the clinical characteristics of molecular profiles in TC have yet to be elucidated. Therefore, to further understand the molecular mechanisms of TC, an multi-method study may offer novel insight for TC prevention and treatment (15).

MicroRNAs (miRNAs/miRs) contain ~19–25 nucleotides and are endogenous non-coding RNAs with gene-regulating functions (16–19). miRNAs are critical in the biological processes of diversified human carcinomas. For instance, they participate in extensive biological actions, including cell proliferation, invasion and apoptosis (18,20–23). Previous studies have demonstrated that miR-193a-3p is a neoplasm suppressor in various carcinomas, including hepatocellular cancer (24), gastric cancer (25,26), lung carcinoma (27), breast carcinoma (28) and colorectal carcinoma (29,30). To the best of the authors' knowledge, thus far only one study has investigated the association between miR-193a-3p and medullary thyroid carcinoma (31); however, a limitation of this study was the small sample size, which prevented a comprehensive description and analysis of TC. To further comprehend the potential molecular mechanisms, it is necessary to examine miR-193a-3p expression in TC using a larger volume of data.

Cyclin D1 (CCND1), a member of the highly conserved cyclin family, can function as a modulator of cyclin-dependent kinase (CDK)4 or CDK6, and has an important role in adjusting the progression of the cell cycle (32,33). Previous studies revealed that CCND1 has a crucial role in promoting proliferation, migration and tumor metastasis (34,35) in cancers such as lung cancer (33), gastric cancer (36) and renal cell cancer (37). CCND1 has been reported to exhibit a high expression in TC tissues and to be associated with invasive behavior (38).

The present study examined TC specimen information from The Cancer Genome Atlas (TCGA) to assess the expression levels of miR-193a-3p and CCND1, and their association with clinical parameters. The data of miR-193a-3p and CCND1 were extracted and validated via ArrayExpress databases and the Gene Expression Omnibus (GEO). Then, the candidate target genes of miR-193a-3p were identified using miRWalk 3.0 and overlapped with the upregulated genes in TC identified using TCGA database. The miR-193a-3p candidate target genes were further investigated using Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and protein-protein interaction (PPI) network enrichment analyses. According to the bioinformatics analysis of the present study, a hub gene was found in TC, and the targeting regulatory relations between the hub gene and miR-193a-3p were confirmed by a dual luciferase assay. By performing a meta-analysis and bioinformatics analysis, the present study revealed the latent molecular mechanisms of miR-193a-3p, as well as its associations with the identified hub gene, which may lead to TC.

Materials and methods <sec> <title>miR-193a-3p expression in TC from public databases and the literature

TCGA is a pool of molecular datasets for at least 30 types of cancers, including TC (39). The present study explored TCGA to determine miR-193a-3p expression in TC tissues. miRNA expression data of 510 TC and 59 normal samples were acquired, along with the accompanying clinical information, from TCGA, up to December 1, 2018 (40). Chip datasets (GSE40807, GSE62054 and GSE73182) from GEO were also searched to examine the profiling of miR-193a-3p expression in TC (41–43). The following keywords were used: (papillary OR medullary OR follicular OR anaplastic OR thyroid) AND (carcinoma OR cancer OR adenocarcinoma OR tumor OR neoplas* OR malignan*) AND (microRNA OR miR OR miRNA), where ‘*’ refers to a wildcard search. The public database of microarray gene expression, ArrayExpress (E-MTAB-736) (44) was also used. In addition, literature that included miR-193a-3p expression in TC was searched for in 13 online databases: Wiley Online Library (https://onlinelibrary.wiley.com), Ovid (https://www.ovid.com), LILACS (https://lilacs.bvsalud.org), Web of Science (http://www.isiknowledge.com), PubMed (https://www.ncbi.nlm.nih.gov/pubmed), Science Direct (https://www.sciencedirect.com), Cochrane Central Register of Controlled Trials (https://www.cochranelibrary.com), EMBASE (https://www.embase.com), Google Scholar (https://scholar.google.com), Chong Qing VIP (http://lib.cqvip.com), Wan Fang (http://www.wanfangdata.com), Chinese CNKI (https://www.cnki.net) and the China Biology Medicine Disc (http://www.sinomed.ac.cn). The studies needed to meet the following requirements for inclusion: i) The miR-193a-3p expression data in TC could be tested in humans; and ii) the relevant information of miR-193a-3p could be abstracted from the literature. All expression data and clinical information connected to miR-193a-3p were extracted.

Comprehensive statistical analysis of TCGA, GEO, ArrayExpress and the literature

The expression levels of both TC and non-cancerous samples were visualized using scatter diagrams and receiver operating characteristic (ROC) curves created using GraphPad Prism 6.0 (GraphPad Software, Inc.). Student's t-test was performed to compare the expression of TC and non-cancer samples, as well as the association between clinicopathological parameters and miR-193a-3p from TCGA database. One-way analysis of variance was used for three or more groups. All miR-193a-3p expression data abstracted from various databases were normalized to log2, and P<0.05 was considered to indicate a statistically significant difference. An all-sided analysis was performed by employing STATA 12.0 software (StataCorp LLC). The pooled standard mean difference (SMD) was applied to evaluate miR-193a-3p expression. χ² and I² tests were computed to assess the heterogeneity within the meta-analysis. The Mantel-Haenszel fixed-effects model was selected if there was no prominent heterogeneity (I²<50%). Otherwise, a random-effects model was applied (I²>50%) (45); meanwhile, heterogeneity analysis was performed to discover the sources of heterogeneity. Subsequently, a summary (s)ROC was created to indicate the ability of miR-193a-3p to identify TC compared with a normal sample (46–48).

Prediction of miR-193a-3p candidate target genes and their molecular functions

To further search for the latent molecular functions of miR-193a-3p in TC, bioinformatics analysis was performed. First, the target genes of miR-193a-3p were predicted using 12 platforms [miRWalk 2.0 (version 2; http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2), PITA (version 6; http://genie.weizmann.ac.il/pubs/mir07/mir07_exe.html), PicTar2 (https://pictar.mdc-berlin.de), RNAhybrid 2.1 (https://bibiserv.cebitec.uni-bielefeld.de/rnahybrid), MicroT4 v4.0 (version 5; http://diana.imis.athena-innovation.gr), miRDB 4.0 (http://www.mirdb.org), miRanda-rel2010 (http://www.microrna.org/microrna/getDownloads.do), TargetScan 7.2 (version 7.2; http://www.targetscan.org), RNA22 v2 (https://cm. jefferson.edu/rna22-full-sets-of-predictions), miRBridge (http://www.ncbi.nlm.nih.gov/pubmed/?term=20385095), miRNAMap (ftp://mirnamap.mbc.nctu.edu.tw/miRNAMap2) and miRMap (https://mirmap.ezlab.org)]. The predicted genes exhibited in the 12 platforms were selected: 3,984 candidate target genes. Log2 conversion and normalization was performed for the gene chips and RNA sequencing from the GEO and TCGA databases. Differentially expressed genes in microarrays and RNA sequencing data were also screened out by the limma package (version 3.42.2) of R language (R version 3.6.2; http://www.r-project.org) (49). Integration of differentially expressed genes identified from gene chips and RNA sequencing was conducted via RobustRankAggreg (version 1.1; https://cran.r-project.org/web/packages/RobustRankAggreg). The overexpressed genes in TC from the TCGA and GEO databases were calculated by selecting the following criteria: P-adj<0.05 and any upregulated genes with a log2-fold change (FC)>1. The candidate target genes obtained with the online prediction tools in TCGA and GEO were then overlapped and presented as Venn diagrams (50). Then, the overlapping target genes were used to study molecular mechanisms via GO (51), KEGG pathway (52), Disease Ontology (DO) (53) and PPI network analyses. Bioinformatics analyses were implemented using clusterprofiler package (version 3.10) of R language (54). The ggplot2 package (version 3.3.0) from R language was utilized to visualize the results of the functional analysis (55). STRING 11.0 (http://string.embl.de) was also used to generate a PPI network, which revealed the connection among the overlapping related genes (56).

Expression of CCND1 in TC samples from the TCGA and GEO databases

The clinical value of CCND1, whose expression data was extracted from GEO and TCGA, was further explored. CCND1 expression data and its clinical information were acquired from TCGA. The GEO database was also mined to obtain chip datasets from TC samples using the following keywords: (papillary OR medullary OR follicular OR anaplastic OR thyroid) AND (carcinoma OR tumor OR cancer OR adenocarcinoma OR neoplas* OR malignan*) AND (Cyclin D1 OR G1/S-Specific Cyclin-D1 OR PRAD1 Protein OR B-Cell CLL/Lymphoma 1 OR U21B31 OR BCL-1 Oncogene OR BCL1 OR PRAD1 Oncogene OR Parathyroid Adenomatosis 1 OR D11S287E OR B-Cell Lymphoma 1 Protein). Filtering condition: Series [Entry type], Homo sapiens [Organism]. A total of 13 datasets were obtained: GSE3678, GSE6004, GSE6339, GSE9115, GSE27155, GSE29265, GSE33630, GSE35570, GSE50901, GSE53072, GSE53157, GSE58689 and GSE65144 (57–67). Statistical analysis of CCND1 was also performed. The methods used were the same as those used above for evaluating the expression of miR-193a-3p.

Cell culture and transfection

The 293 cell line was obtained from Huzhou Hippo Biotechnology Co., Ltd. and cultured in DMEM (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin. Cells were cultured in an incubator at 37°C with 5% CO₂. miR-193a-3p mimic (5′-AACUGGCCUACAAAGUCCCAGU-3′), miR-146b-5p mimic (5′-UGAGAACUGAAUUCCAUAGGCUG-3′) and mimic control (5′-UUUGUACUACACAAAAGUACUG-3′) were synthesized and obtained from Hippobio Co., Ltd. miR-193a-3p mimic, miR-146b-5p mimic and their mimic control (all 75 pM) were transfected into 2.5×10⁵ 293 cells/well using Lipofectamine^® 3000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. Transfection efficiency was measured by reverse transcription-quantitative PCR (RT-qPCR) after 48 h.

RNA extraction and RT-qPCR

Cellular RNA was extracted from 293 cells with TRIzol^© reagent (Tiangen Biotech Co., Ltd.). RevertAid Reverse Transcriptase (Invitrogen; Thermo Fisher Scientific, Inc.) was used to reverse transcribe miRNA according to the manufacturer's protocol. The expression of miR-193a-3p and miR-146b-5p was performed by qPCR using PerfectStart Green qPCR SuperMix (Transgen Biotech Co., Ltd.) on an ABI Q1 RT-qPCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.). U6 was used as an internal reference. The relevant primer sequences were as follows: miR-193a-3p forward, 5′-GCCGAGAACTGGCCTACAAA-3′ and reverse, 5′-CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGACTGGGAC-3′; miR-146b-5p forward, 5′-GCCGAGTGAGAACTGAATTCC-3′ and reverse, 5′-CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGCAGCCTAT-3′; U6 forward, 5′-CTCGCTTCGGCAGCACA-3′ and reverse, 5′-AACGCTTCACGAATTTGCGT-3′. miR-193a-3p and miR-146b-5p expression levels were calculated by the 2^−∆∆Cq method (68).

Validation of the association between miR-193a-3p and the hub gene

The protein with the most connections was selected for further investigation. 293 cells exhibit a high transfection efficiency and were thus selected for the luciferase activity assay. The wild-type (Wt) CCND1-3′ untranslated region (UTR) and seed region mutant (Mut) of the miR-193a-3p binding site were subcloned into the pGL3 system (Promega Corporation). Its corresponding positive control [Wt tumor necrosis factor receptor-associated factor 6 (TRAF6)-3′ UTR + miR-146b-5p] was also subcloned into the pGL3 system (69,70). Subsequently, 1×10⁵ 293 cells/well were co-transfected with 100 ng Wt CCND1-3′ UTR or Wt TRAF6-3′ UTR vector and 400 ng miRNA mimic or negative control (NC) plasmid using X-tremeGENE™ HP DNA transfection reagent [Roche Diagnostics (Shanghai) Co., Ltd.]. Then, 2 days following incubation, firefly luciferase activity was assessed using a Dual-Luciferase Reporter assay system (Promega Corporation) in accordance with the manufacturer's protocols. Firefly luciferase activity was normalized to Renilla luciferase activity. Student's t-test was used to compare mimics and mimic control for each luciferase plasmid. Pearson's correlation analysis was also conducted to analyze the relationship between miR-193a-3p and CCND1, and P<0.05 was considered to indicate a statistically significant difference. Hub gene expression between the TC samples and the normal samples was explored via immunohistochemistry using The Human Protein Atlas (71).

Results <sec> <title>Downregulated miR-193a-3p expression in TC and its clinical significance from TCGA

The expression of miR-193a-3p in the TC group was 3.00±0.75 and that in the non-cancerous group was 3.88±0.73. miR-193a-3p exhibited significantly reduced expression in 510 TC samples compared with in 59 non-cancer controls (P<0.001; Fig. 1A). The ROC curve of miR-193a-3p was computed with an area under the curve (AUC) of 0.802 (P<0.001; Fig. 2A), which reflected the moderate value of miR-193a-3p to differentiate TC from the non-cancerous groups. The cut-off value was 3.444 (sensitivity 71.2% and specificity 79.7%). miR-193a-3p expression and clinical parameters are displayed in Table I. The miR-193a-3p levels in females were notably greater than those in males (P=0.004). miR-193a-3p was markedly decreased in individuals ≤60 years of age compared with those >60 years (P=0.020). ln addition, the number of distant metastases showed a negative association with miR-193a-3p expression levels (P=0.048).

miR-193a-3p expression in TC verified via GEO, ArrayExpress and literature analyses

Subsequently, in other online databases, data from 4 chips (GSE40807, GSE62054, GSE73182 and E-MTAB-736) were acquired from the GEO and ArrayExpress databases, which provided the expression information on miR-193a-3p in 88 TC and 75 non-cancerous tissues (Table II). The literature was also searched in 13 online databases, but the data from one study could not be extracted. All 4 datasets obtained from the GEO and ArrayExpress databases revealed that miR-193a-3p expression levels in TC were greater compared with non-TC controls, although two of these four datasets had P-values >0.05 (Fig. 1B-E). ROC analysis was also used to estimate the capacity of miR-193a-3p in distinguishing TC from non-cancer tissues (Fig. 2B-E); three of the four chips demonstrated that miR-193a-3p had a moderate diagnostic value for TC. miR-193a-3p expression data from TCGA, GEO and ArrayExpress, which provided 598 TC and 134 non-cancerous samples, were combined for meta-analysis. The SMD of miR-193a-3p was −1.00 [P<0.001; 95% CI, (−1.21, −0.79); Fig. 3A] via the fixed-effects model, and the heterogeneity test was P=0.46 (I²=0%). The AUC of the sROC was 0.80 (95% CI, 0.76–0.83), indicating a moderate ability to differentiate TC from non-cancer samples. The combined sensitivity and specificity were 0.69 (95% CI, 0.59–0.78) and 0.82 (95% CI, 0.67–0.91), respectively (Fig. 3B). Publication bias was performed and showed that there was no conspicuous publication bias among the datasets (Begg's test and Egger's test were 0.81 and 0.16, respectively; Fig. 3C and D).

GO annotation, KEGG pathway, DO and PPI network analysis

The prediction of the candidate target genes of miR-193a-3p was conducted using miRWalk 3.0, in which 3,984 potential mRNA candidate target genes were discovered. Next, 1,490 and 132 genes with elevated expression were determined from the TCGA and GEO databases, respectively. A total of 28 overlapping genes were eventually identified (Fig. 4A). The properties of these target genes were analyzed using the clusterprofiler R package. The results indicated that ‘response to nutrient levels’ was the most significantly enriched biological process (BP); with respect to cellular components (CC), the genes were mainly enriched in the ‘lamellar body’. In terms of molecular function (MF), ‘sulfur compound binding’ was the most enriched (Fig. 5A-C; Table III). However, no KEGG pathways were significantly enriched with these genes. DO analysis was also performed to discover related diseases caused by these genes. The results identified that ‘cell type benign neoplasm’ was the most enriched (Fig. 5D; Table III). Then, the target genes were put into the STRING online website to construct a protein-protein interaction network (Fig. 4B). In the present study, CCND1 attracted attention as a hub gene, as it had the most connections among the proteins; therefore, the targeting association between CCND1 and miR-193a-3p was selected for further investigation.

Overexpression of CCND1 in TC and its clinical significance

The expression value and clinical significance of CCND1 in TC was verified using data from two different sources (TCGA and GEO databases; Table IV). The expression of CCND1 in the TC group from TCGA database was 13.36±0.74 and that in the non-cancerous group was 11.66±0.49. CCND1 was significantly overexpressed in 513 TC samples compared with 59 non-cancerous samples (P<0.001; Fig. 6A). The AUC for upregulated CCND1 expression in TC was 0.965 (P<0.001; Fig. 7A), which indicated the high capacity of the expression value of CCND1 to differentiate TC from normal samples. The cut-off value was 12.628 (sensitivity 86.9% and specificity 100%). Differential CCND1 expression was not detected for the clinical pathological parameters analyzed. The associations between the expression of CCND1 and clinical pathological parameters are summarized in Table V. The expression value of CCND1 was also calculated from the chip arrays of the GEO database, which included 384 TC and 316 non-cancer controls (GSE3678, GSE6004, GSE6339, GSE9115, GSE27115, GSE29265, GSE33630, GSE35570, GSE50901, GSE53072, GSE53157, GSE58689 and GSE65144). Except for GSE53072, GSE53157 and GSE65144, the remaining chip arrays revealed significantly upregulated expression of CCND1 in the TC tissues compared with non-cancerous tissues (P<0.05; Fig. 6B-N). The GSE53072, GSE53157 and GSE65144 chip arrays displayed non-significant trends towards upregulated expression of CCND1 in the TC tissues. AROC curve analysis of CCND1 was also performed and the results are shown in Fig. 7B-N. Then, CCND1 expression data from TCGA and GEO databases, which provided 897 TC and 193 non-cancerous tissues, were subjected to meta-analysis. The pooled SMD of CCND1 was 1.83 (P<0.001; 95% CI, 1.41–2.26; Fig. 8A) by the random effects model, and the test for heterogeneity was P<0.01 (I²=79.9%). The sROC curve of the TCGA and GEO expression data is shown in Fig. 8B. The publication bias was evaluated by a funnel chart: Begg's test and Egger's test were 0.44 and 0.75, respectively, which indicated that there was no conspicuous publication bias among the datasets (Fig. 8C and D). Furthermore, the AUC of the sROC was 0.91 (95% CI, 0.89–0.94) and the combined sensitivity and specificity were 0.85 (95% CI, 0.81–0.89) and 0.98 (95% CI, 0.90–1.00), respectively. The results revealed that CCND1 may be a good biomarker to discriminate TC tissues from non-cancerous tissues.

Validation of the targeting regulatory relation between miR-193a-3p and CCND1

The putative miR-193a-3p binding site in CCND1 3′ UTR was identified (Fig. 9A). The targeting regulatory association between miR-193a-3p and CCND1 was investigated in 293 cells following transfection with miR-193a-3p or miR-146b-5p mimics. The findings indicated that miR-193a-3p reduced the luciferase activity of the Wt CCND1 3′ UTR, demonstrating a direct combination between CCND1 and miR-193a-3p (P<0.05; Fig. 9B-D). Furthermore, the luciferase activity of CCND1 3′ UTR (Mut) was not reduced in the mimic-transfected cells. miR-146-5p reduced the luciferase activity of the Wt TRAF6-3′ UTR, indicating that the experiment and its results were reliable. Pearson correlation analysis was also conducted to evaluate the association between miR-193a-3p and CCND1; however, no linear correlation was observed between CCND1 and miR-193a-3p (r=−0.163; Fig. 9E). The Human Protein Atlas database was utilized to explore the protein levels of CCND1. Consistent with the gene expression data, CCND1 protein expression was higher in TC than in non-cancerous tissues, as shown in Fig. 10.

Discussion

TC is a frequent endocrine malignancy of the endocrine system (72). The occurrence rate of TC has been increasing worldwide (73). The main therapy method of TC is thyroidectomy and radioiodine treatment (74). To the best of the authors' knowledge, there is currently no effective drug for the treatment for TC. There is increasing evidence that abnormal miRNA expression levels give rise to TC tumorigenesis and progression. Prior studies have demonstrated that various miRNAs may aid in the diagnosis of TC and help formulate more individualized therapeutic management strategies (75–78). miR-193a-3p is involved in certain biological processes, including apoptosis, proliferation, invasion, metastasis and migration (79). A number of studies have demonstrated that miR-193a-3p is expressed at low levels in different human cancers, including colon cancer (80), lung cancer (81,82), breast cancer (28) and malignant pleural mesothelioma (83). Nevertheless, the expression levels, as well as its mechanisms, in TC remain to be elucidated. Hence, a comprehensive meta-analysis was conducted to evaluate clinical valuation of miR-193a-3p in TC. GO, KEGG pathway and PPI analyses were performed to search for the latent biological mechanisms of miR-193a-3p in TC. The results indicated that CCND1 served as the most important hub gene. Subsequently, the relationship between miR-193a-3p and CCND1 was validated through a dual luciferase assay.

To the best of the authors' knowledge, the present study is the first to survey the expression levels and clinical value of miR-193a-3p in TC by extracting expression data from TCGA, GEO and ArrayExpress. The present study primarily scrutinized the miR-193a-3p expression between 510 TC and 59 non-cancerous thyroid samples using TCGA database. The outcomes revealed that miR-193a-3p had low expression in TC. Subsequently, the GEO database and ArrayExpress were used to validate miR-193a-3p expression in TC. A total of 2 of the 4 chip arrays also revealed that a low miR-193a-3p expression is significant in TC. Although the remaining 2 chip arrays did not display a significant downregulation in TC tissues, they indicated the downregulated expression tendency of miR-193a-3p in TC. According to the results of the present study, miR-193a-3p may provide a biomarker to test the occurrence and development of TC. However, in the study by Santarpia et al (31), the result was the opposite: miR-193a-3p was overexpressed in TC compared with non-cancerous groups. The observation of overexpressed miR-193a-3p may be caused by the small sample size of the study. That significantly downregulated miR-193a-3p in TC was observed in the present study was credible due to the quantity of sample data that was obtained from several public databases. Analysis of the sROC in miR-193a-3p from TCGA, GEO and ArrayExpress databases demonstrated that the expression levels may have a moderate ability to differentiate between TC patients and non-cancerous controls with an AUC of 0.80. At the same time, its sensitivity and specificity were 0.69 and 0.82, respectively. Additionally, downregulated miR-193a-3p was association with age, metastasis and sex in TCGA. Although the present study identified that downregulated miR-193a-3p was associated with age, metastasis and sex; how these factors regulate TC cells requires further investigation by in vivo and/or in vitro analysis.

At present, several studies have noted that abnormal miR-193a-3p expression has a pivotal effect on cell biological processes and leads to numerous pathological conditions (79,80,84). For example, Pekow et al revealed that miR-193a-3p is a crucial neoplasm inhibitor in colon carcinoma and facilitates the progression of cancer (80). Lin et al (84). demonstrated that low miR-193a-3p expression is related to a poor disease outcome in colorectal carcinoma. In addition, miR-193a-3p suppresses cell multiplication in prostatic carcinoma by targeting CCND1 (85). However, little research has been performed into the molecular mechanisms of miR-193a-3p in TC. To further study the underlying mechanisms regarding the regulation of miR-193a-3p in TC, the present study conducted a bioinformatics analysis of the candidate target genes of miR-193a-3p. A total of 28 candidate target genes of miR-193a-3p were gathered and GO analysis was performed, which indicated that the candidate target genes markedly assembled in ‘response to nutrient levels’ for BP, ‘lamellar body’ for CC and ‘sulfur compound binding’ for MF. GO analysis revealed that miR-193a-3p target genes were mainly concentrated in ‘cell adhesion’, which exerts an oncogenic role in the progression of TC. In addition, PPI analysis was performed, and it was found that CCND1 was situated at the core of the PPI network. CCND1 had the most connections among proteins, which may manifest in the way the gene contributes to TC.

A previous study by Li et al (35) reported that CCND1 plays a key role in facilitating migration and tumor metastasis. Liang and Sun (86) reported that an upregulation of CCND1 in thyroid cancer tissues is markedly associated with the clinical stage of TC, indicating that it could be considered as a biomarker in clinical settings. A study by Jeon et al (87) showed that CCND1 is clearly overexpressed in TC, and may be involved in the occurrence and development of the disease. Lamba Saini et al (88) demonstrated that CCND1 and its variants are significantly overexpressed in TC, and that it should serve as a diagnostic marker for TC. Investigating the mechanism of CCND1 expression levels is crucial due to the broader roles of CCND1 in TC tissues. From the present study, the results calculated from the TCGA database demonstrated that CCND1 exhibited a notably low expression in TC compared with non-cancerous tissues. However, differential expression of CCND1 was not obtained for the clinical parameters analyzed. The present study also included 13 microarrays from the GEO database. In addition to GSE53072, GSE53157, GSE6339 and GSE65144, other chip arrays all displayed a significant upregulation of CCND1 expression in TC compared to non-cancerous tissues. Although the remaining 4 chip arrays did not show statistical significance, they all showed an increasing trend in CCND1 expression levels in TC. From the sROC analysis of miR-193a-3p, the AUC was 0.91. The results showed that CCND1 may have a high value for differentiating TC from non-cancerous tissue and may serve as a prognostic biomarker in TC.

The study by Liu et al (85) identified that miR-193a-3p acts as a key component inhibiting prostate cancer, which could induce G1-phase arrest by targeting CCND1. Chou et al (25) demonstrated that miR-193a-3p suppresses the aggression and progression of gastric cancer by targeting CCND1 expression. Tsai et al (89) also demonstrated that miR-193a-3p may serve as an underlying neoplasm inhibitor in breast carcinoma, which could inhibit cell growth by suppressing CCND1. To this end, the present study performed a dual luciferase assay, and a regulatory association between miR-193a-3p and CCND1 was validated. In summary, the findings of the present study revealed that miR-193a-3p may regulate CCND1 expression to affect the tumor cell cycle, cell proliferation, differentiation and metabolism. Nevertheless, further research is required to test this hypothesis.

However, in the present study, some limitations should be acknowledged. First, it lacks further in vitro and in vivo testing, such as reverse transcription-quantitative PCR. These methods are pivotal to enhancing the understanding of how miR-193a-3p works in relation to CCND1 in TC. Second, the present study only focused on the analysis of differential miRNAs in tissues. Other samples, such as blood, should also be assessed.

In summary, the present study gathered a great amount of data from TCGA, GEO, and ArrayExpress databases, and validated the clinical value of miR-193a-3p and CCND1. The results showed that miR-193a-3p expression was evidently downregulated in TC, while CCND1 expression was markedly upregulated. These results may help to diagnose TC and predict the prognosis of TC when thyroid tissues are obtained from a fine needle biopsy. Bioinformatics analysis was next performed to clarify the molecular mechanisms of miR-193a-3p. In light of the bioinformatics analysis, CCND1 was regarded as the most important hub gene in TC. Subsequently, a dual luciferase assay was performed to corroborate the targeting regulatory association between miR-193a-3p and CCND1. The results demonstrated that miR-193a-3p markedly contributes to TC via particular pathways, and both miR-193a-3p and CCND1 may serve as potential biological markers of TC.

Acknowledgements

Not applicable.

Funding

This study was supported by Fund of National Natural Science Foundation of China (grant nos. NSFC81060202 and NSFC81260222), the Fund of Guangxi Key R&D Project Plan (grant no. AB17195020) and the Future Academic Star of Guangxi Medical University (grant nos. WLXSZX19050 and WLXSZX19055).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

YYP, HY, XJL and RW contributed to the design of the study; XJL and RW wrote the manuscript; DYW, PL, DHP, LJZ and YH collected the data, performed the statistical analysis and interpreted the data; and LS, YYQ, YHL, JNL, JLY, QQL, JW and JM contributed to the data collection and statistical analysis. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References 1

Konturek

Barczyński

Stopa

Nowak

Trends in Prevalence of Thyroid Cancer Over Three Decades: A Retrospective Cohort Study of 17,526 Surgical Patients

World J Surg405385442016

10.1007/s00268-015-3322-z

26560150

van der Zwan

Mallone

van Dijk

Bielska-Lasota

Otter

Foschi

Baudin

Links

RARECARE WG

Carcinoma of endocrine organs: Results of the RARECARE project

Eur J Cancer48192319312012

10.1016/j.ejca.2012.01.029

22361014

Miller

Goding Sauer

Ortiz

Fedewa

Pinheiro

Tortolero-Luna

Martinez-Tyson

Jemal

Siegel

Cancer Statistics for Hispanics/Latinos, 2018

CA Cancer J Clin684254452018

10.3322/caac.21494

30285281

Lin

Guo

Shi

Yang

Dang

Wei

Chen

Development of a prognostic index based on an immunogenomic landscape analysis of papillary thyroid cancer

Aging (Albany NY)114805002019

10.18632/aging.101754

30661062

Zarkesh

Zadeh-Vakili

Akbarzadeh

Fanaei

Hedayati

Azizi

The role of matrix metalloproteinase-9 as a prognostic biomarker in papillary thyroid cancer

BMC Cancer1811992018

10.1186/s12885-018-5112-0

30509240

Siegel

Miller

Jemal

Cancer statistics, 2018

CA Cancer J Clin687302018

10.3322/caac.21442

29313949

Carling

Udelsman

Thyroid cancer

Annu Rev Med651251372014

10.1146/annurev-med-061512-105739

24274180

Lin

Wen

Zeng

Peng

Pan

Comprehensive analysis of the clinical significance and prospective molecular mechanisms of differentially expressed autophagy-related genes in thyroid cancer

Int J Oncol536036192018

29749543

Liu

Chen

miR-144-3p promotes the tumor growth and metastasis of papillary thyroid carcinoma by targeting paired box gene 8

Cancer Cell Int18542018

10.1186/s12935-018-0550-y

29632436

Acquaviva

Visani

Repaci

Rhoden

de Biase

Pession

Giovanni

Molecular pathology of thyroid tumours of follicular cells: A review of genetic alterations and their clinicopathological relevance

Histopathology726312018

10.1111/his.13380

29239040

Riesco-Eizaguirre

Santisteban

Molecular biology of thyroid cancer initiation

Clin Transl Oncol96866932007

10.1007/s12094-007-0125-1

18055323

DeLellis

Pathology and genetics of thyroid carcinoma

J Surg Oncol946626692006

10.1002/jso.20700

17131411

Liu

You

Sui

Shen

Zhang

Yang

Yao

Yang

Yin

Prognostic value of a two-microRNA signature for papillary thyroid cancer and a bioinformatic analysis of their possible functions

J Cell BiochemNov22018(Epub ahead of print). doi: 10.1002/jcb.27993 2018

Wang

Huang

Jiang

Gao

A potential biomarker hsa-miR-200a-5p distinguishing between benign thyroid tumors with papillary hyperplasia and papillary thyroid carcinoma

PLoS One13e02002902018

10.1371/journal.pone.0200290

30005075

Vuong

Altibi

Abdelhamid

Ngoc

Quan

Tantawi

Elfil

Elgebaly

Oishi

The changing characteristics and molecular profiles of papillary thyroid carcinoma over time: A systematic review

Oncotarget810637106492017

10.18632/oncotarget.12885

27793009

Tricoli

Jacobson

MicroRNA: Potential for Cancer Detection, Diagnosis, and Prognosis

Cancer Res67455345552007

10.1158/0008-5472.CAN-07-0563

17510380

Boufraqech

Klubo-Gwiezdzinska

Kebebew

MicroRNAs in the thyroid

Best Pract Res Clin Endocrinol Metab306036192016

10.1016/j.beem.2016.10.001

27923454

Macha

Seshacharyulu

Krishn

Pai

Rachagani

Jain

Batra

MicroRNAs (miRNAs) as biomarker(s) for prognosis and diagnosis of gastrointestinal (GI) cancers

Curr Pharm Des20528752972014

10.2174/1381612820666140128213117

24479799

Parvex

Are microRNA potential biomarkers in children with idiopathic nephrotic syndrome?

EBioMedicine3927282019

10.1016/j.ebiom.2018.12.045

30584009

Farazi

Spitzer

Morozov

Tuschl

miRNAs in human cancer

J Pathol2231021152011

10.1002/path.2806

21125669

Shen

Law

Chan

MicroRNA expression and its implications for diagnosis and therapy of gallbladder cancer

Oncotarget613914139212015

10.18632/oncotarget.4227

26040010

Peng

Xue

Fan

Wang

Lian

Zhai

Lian

Qin

Zhao

Integrated analysis of dysregulated long non-coding RNAs/microRNAs/mRNAs in metastasis of lung adenocarcinoma

J Transl Med163722018

10.1186/s12967-018-1732-z

30587197

Sun

miR-29a-3p inhibits growth, proliferation, and invasion of papillary thyroid carcinoma by suppressing NF-κB signaling via direct targeting of OTUB2

Cancer Manag Res1113232018

10.2147/CMAR.S184781

30588107

Liu

Ren

Luo

Rong

Chen

Dang

Down-Regulation of miR-193a-3p Dictates Deterioration of HCC: A Clinical Real-Time qRT-PCR Study

Med Sci Monit21235223602015

10.12659/MSM.894077

26263159

Chou

Wang

Kang

Tsai

miR-193a-5p and −3p Play a Distinct Role in Gastric Cancer: miR-193a-3p Suppresses Gastric Cancer Cell Growth by Targeting ETS1 and CCND1

Anticancer Res38330933182018

10.21873/anticanres.12596

29848678

Huang

Luo

Yang

LINC00152 down-regulated miR-193a-3p to enhance MCL1 expression and promote gastric cancer cells proliferation

Biosci Rep38BSR201716072018

10.1042/BSR20171607

29339419

Deng

Yan

Lin

Liu

Geng

Zhu

Liu

Quantitative proteomic analysis of the metastasis-inhibitory mechanism of miR-193a-3p in non-small cell lung cancer

Cell Physiol Biochem35167716882015

10.1159/000373981

25833338

Liu

Zhou

Sun

Liu

Hua

Zhao

Gao

PTP1B markedly promotes breast cancer progression and is regulated by miR-193a-3p

FEBS J286113611532019

10.1111/febs.14724

30548198

Takahashi

Ohnuma

Unno

Yoshino

Ouchi

Takahashi

Yamada

Shimodaira

Ishioka

microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer

BMC Cancer177232017

10.1186/s12885-017-3739-x

29115941

Mamoori

Wahab

Islam

Lee

Vider

Gopalan

Lam

Clinical and biological significance of miR-193a-3p targeted KRAS in colorectal cancer pathogenesis

Hum Pathol711451562018

10.1016/j.humpath.2017.10.024

29104111

Santarpia

Calin

Adam

Fusco

Giunti

Thaller

Paladini

Zhang

Jimenez

A miRNA signature associated with human metastatic medullary thyroid carcinoma

Endocr Relat Cancer208098232013

10.1530/ERC-13-0357

24127332

Baldin

Lukas

Marcote

Pagano

Draetta

Cyclin D1 is a nuclear protein required for cell cycle progression in G1

Genes Dev78128211993

10.1101/gad.7.5.812

8491378

Zhao

Liu

Zhen

Chen

Liu

Deng

Liang

Dual roles of miR-374a by modulated c-Jun respectively targets CCND1-inducing PI3K/AKT signal and PTEN-suppressing Wnt/β-catenin signaling in non-small-cell lung cancer

Cell Death Dis9782018

10.1038/s41419-017-0103-7

29362431

Yang

Liu

Overexpression of the transcription factor FOXP3 in lung adenocarcinoma sustains malignant character by promoting G1/S transition gene CCND1

Tumour Biol37739574042016

10.1007/s13277-015-4616-3

26676638

Wang

Prendergast

Pestell

Cyclin D1 functions in cell migration

Cell Cycle5244024422006

10.4161/cc.5.21.3428

17106256

Huang

Han

Yang

Zhu

Zhang

Wei

Gao

HNRNPK inhibits gastric cancer cell proliferation through p53/p21/CCND1 pathway

Oncotarget81033641033742017

10.18632/oncotarget.21873

29262567

Xue

Qin

Zhang

Zheng

Cao

Wang

Genetic polymorphisms in cyclin D1 are associated with risk of renal cell cancer in the Chinese population

Oncotarget880889808992017

10.18632/oncotarget.20720

29113352

Cheng

Serra

Mercado

Ezzat

Asa

A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior

Clin Cancer Res17238523942011

10.1158/1078-0432.CCR-10-2837

21389096

Deng

Brägelmann

Schultze

Perner

Web-TCGA: An online platform for integrated analysis of molecular cancer data sets

BMC Bioinformatics17722016

10.1186/s12859-016-0917-9

26852330

Chandran

Medvedeva

Barmada

Blood

Chakka

Luthra

Ferreira

Wong

Lee

Zhang

TCGA Expedition: A Data Acquisition and Management System for TCGA Data

PLoS One11e01653952016

10.1371/journal.pone.0165395

27788220

Barrett

Wilhite

Ledoux

Evangelista

Kim

Tomashevsky

Marshall

Phillippy

Sherman

Holko

NCBI GEO: Archive for functional genomics data sets - update

Nucleic Acids Res 41DD991D9952013

Lassalle

Zangari

Popa

Ilie

Hofman

Long

Patey

Tissier

Belléannée

Trouette

MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib

Oncotarget730461304782016

10.18632/oncotarget.8458

27036030

Minna

Romeo

Dugo

De Cecco

Todoerti

Pilotti

Perrone

Seregni

Agnelli

Neri

miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma

Oncotarget712731127472016

10.18632/oncotarget.7262

26871295

Rossing

Borup

Henao

Winther

Vikesaa

Niazi

Godballe

Krogdahl

Glud

Hjort-Sørensen

Down-regulation of microRNAs controlling tumourigenic factors in follicular thyroid carcinoma

J Mol Endocrinol4811232012

10.1530/JME-11-0039

22049245

Ioannidis

Patsopoulos

Evangelou

Uncertainty in heterogeneity estimates in meta-analyses

BMJ3359149162007

10.1136/bmj.39343.408449.80

17974687

Gan

Zhang

Wei

Chen

Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis

Int J Oncol53155715792018

30066858

Deng

Zhang

Gan

Zhang

Chen

The expression of HOXA13 in lung adenocarcinoma and its clinical significance: A study based on The Cancer Genome Atlas, Oncomine and reverse transcription-quantitative polymerase chain reaction

Oncol Lett15855685722018

29805592

Liang

Huang

Tang

Chen

Cen

Shi

Gao

Liu

Clinical value of miR-198-5p in lung squamous cell carcinoma assessed using microarray and RT-qPCR

World J Surg Oncol16222018

10.1186/s12957-018-1320-y

29394946

Ritchie

Phipson

Law

Shi

Smyth

limma powers differential expression analyses for RNA-sequencing and microarray studies

Nucleic Acids Res43e472015

10.1093/nar/gkv007

25605792

Bardou

Mariette

Escudié

Djemiel

Klopp

jvenn: An interactive Venn diagram viewer

BMC Bioinformatics152932014

10.1186/1471-2105-15-293

25176396

The Gene Ontology Consortium

The Gene Ontology Resource: 20 years and still GOing strong

Nucleic Acids Res47D1D330D3382019

10.1093/nar/gky1055

30395331

Kanehisa

Sato

Furumichi

Morishima

Tanabe

New approach for understanding genome variations in KEGG

Nucleic Acids Res 47DD590D5952019

10.1093/nar/gky962

Schriml

Mitraka

Munro

Tauber

Schor

Nickle

Felix

Jeng

Bearer

Lichenstein

Human Disease Ontology 2018 update: Classification, content and workflow expansion

Nucleic Acids Res 47DD955D9622019

10.1093/nar/gky1032

Wang

Han

clusterProfiler: An R package for comparing biological themes among gene clusters

OMICS162842872012

10.1089/omi.2011.0118

22455463

Wickham

ggplot2: Elegant Graphics for Data Analysis

Springer

New York, NY

2016

Szklarczyk

Gable

Lyon

Junge

Wyder

Huerta-Cepas

Simonovic

Doncheva

Morris

Bork

STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets

Nucleic Acids Res 47DD607D6132019

10.1093/nar/gky1131

Vasko

Espinosa

Scouten

Auer

Liyanarachchi

Larin

Savchenko

Francis

de la Chapelle

Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion

Proc Natl Acad Sci USA104280328082007

10.1073/pnas.0610733104

17296934

Fontaine

Mirebeau-Prunier

Franc

Triau

Rodien

Houlgatte

Malthièry

Savagner

Microarray analysis refines classification of non-medullary thyroid tumours of uncertain malignancy

Oncogene27222822362008

10.1038/sj.onc.1210853

17968324

Salvatore

Nappi

Salerno

Jiang

Garbi

Ugolini

Miccoli

Basolo

Castellone

Cirafici

A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma

Cancer Res6710148101582007

10.1158/0008-5472.CAN-07-1887

17981789

Giordano

Kuick

Thomas

Rhodes

Wilhelm

JrVinco

Misek

Sanders

Zhu

Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation

Clin Cancer Res12198319932006

10.1158/1078-0432.CCR-05-2039

16609007

Dom

Tarabichi

Unger

Thomas

Oczko-Wojciechowska

Bogdanova

Jarzab

Dumont

Detours

Maenhaut

A gene expression signature distinguishes normal tissues of sporadic and radiation-induced papillary thyroid carcinomas

Br J Cancer10799410002012

10.1038/bjc.2012.302

22828612

Handkiewicz-Junak

Swierniak

Rusinek

Oczko-Wojciechowska

Dom

Maenhaut

Unger

Detours

Bogdanova

Thomas

Gene signature of the post-Chernobyl papillary thyroid cancer

Eur J Nucl Med Mol Imaging43126712772016

10.1007/s00259-015-3303-3

26810418

Barros-Filho

Marchi

Pinto

Rogatto

Kowalski

High Diagnostic Accuracy Based on CLDN10, HMGA2, and LAMB3 Transcripts in Papillary Thyroid Carcinoma

J Clin Endocrinol Metab100E890E8992015

10.1210/jc.2014-4053

25867809

Pita

Figueiredo

Moura

Leite

Cavaco

Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas

J Clin Endocrinol Metab99E497E5072014

10.1210/jc.2013-1512

24423316

Pita

Banito

Cavaco

Leite

Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas

Br J Cancer101178217912009

10.1038/sj.bjc.6605340

19809427

Rusinek

Swierniak

Chmielik

Kowal

Kowalska

Cyplinska

Czarniecka

Piglowski

Korfanty

Chekan

BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma

PLoS One10e01436882015

10.1371/journal.pone.0143688

26625260

von Roemeling

Marlow

Pinkerton

Crist

Miller

Tun

Smallridge

Copland

Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target

J Clin Endocrinol Metab100E697E7092015

10.1210/jc.2014-2764

25675381

Livak

Schmittgen

Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method

Methods254024082001

10.1006/meth.2001.1262

11846609

Liu

Sun

Shi

Zhou

Bian

Ping

miR-146b-5p functions as a tumor suppressor by targeting TRAF6 and predicts the prognosis of human gliomas

Oncotarget629129291422015

10.18632/oncotarget.4895

26320176

Xiong

Liang

Luo

Chen

The LncRNA NEAT1 Accelerates Lung Adenocarcinoma Deterioration and Binds to Mir-193a-3p as a Competitive Endogenous RNA

Cell Physiol Biochem489059182018

10.1159/000491958

30036873

Uhlén

Fagerberg

Hallström

Lindskog

Oksvold

Mardinoglu

Sivertsson

Kampf

Sjöstedt

Asplund

Proteomics. Tissue-based map of the human proteome

Science34712604192015

10.1126/science.1260419

25613900

Kitahara

Sosa

The changing incidence of thyroid cancer

Nat Rev Endocrinol126466532016

10.1038/nrendo.2016.110

27418023

Vigneri

Malandrino

Vigneri

The changing epidemiology of thyroid cancer: Why is incidence increasing?

Curr Opin Oncol27172015

10.1097/CCO.0000000000000148

25310641

Raue

Frank-Raue

Thyroid Cancer: Risk-Stratified Management and Individualized Therapy

Clin Cancer Res22501250212016

10.1158/1078-0432.CCR-16-0484

27742787

Qiu

Zhang

Zang

Liu

Sun

Xia

Identification of key genes and miRNAs markers of papillary thyroid cancer

Biol Res51452018

10.1186/s40659-018-0188-1

30414611

Nixon

Provatopoulou

Kalogera

Zografos

Gounaris

Circulating thyroid cancer biomarkers: Current limitations and future prospects

Clin Endocrinol (Oxf)871171262017

10.1111/cen.13369

28493290

Zhang

Pan

Yang

Sun

Qiao

Combination of serum microRNAs and ultrasound profile as predictive biomarkers of diagnosis and prognosis for papillary thyroid microcarcinoma

Oncol Rep40361136242018

30542708

Nikiforov

Role Of Molecular Markers In Thyroid Nodule Management: Then And Now

Endocr Pract239799882017

10.4158/EP171805.RA

28534687

Grossi

Salvi

Abeni

Marchina

De Petro

Biological Function of MicroRNA193a-3p in Health and Disease

Int J Genomics201759131952017

10.1155/2017/5913195

29038785

Pekow

Meckel

Dougherty

Huang

Chen

Almoghrabi

Mustafi

Ayaloglu-Butun

Deng

Haider

miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis-Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD

Clin Cancer Res23528152912017

10.1158/1078-0432.CCR-17-0171

28600480

Fan

Zhang

Wang

Zhang

You

Zhang

Liang

Chen

miR-193a-3p is an Important Tumour Suppressor in Lung Cancer and Directly Targets KRAS

Cell Physiol Biochem44131113242017

10.1159/000485491

29183007

Ren

Ding

Huang

Wang

Luo

Dang

Yang

Chen

Expression and clinicopathological significance of miR-193a-3p and its potential target astrocyte elevated gene-1 in non-small lung cancer tissues

Cancer Cell Int15802015

10.1186/s12935-015-0227-8

26257582

Williams

Kirschner

Cheng

Hanh

Weiss

Mugridge

Wright

Linton

Kao

Edelman

miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma

Oncotarget623480234952015

10.18632/oncotarget.4346

26125439

Lin

Duan

Sheng

Gao

Huang

Decreased expression of miR-193a-3p is associated with poor prognosis in colorectal cancer

Oncol Lett14106110672017

10.3892/ol.2017.6266

28693274

Liu

Liang

Zhu

Jin

Wang

MicroRNA-193a-3p inhibits cell proliferation in prostate cancer by targeting cyclin D1

Oncol Lett14512151282017

29142597

Liang

Sun

Identification of key genes of papillary thyroid cancer using integrated bioinformatics analysis

J Endocrinol Invest41123712452018

10.1007/s40618-018-0859-3

29520684

Jeon

Kim

Jeong

Bae

Jung

CCND1 Splice Variant as A Novel Diagnostic and Predictive Biomarker for Thyroid Cancer

Cancers (Basel)104372018

10.3390/cancers10110437

Lamba Saini

Weynand

Rahier

Mourad

Hamoir

Marbaix

Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential

Diagn Pathol10322015

10.1186/s13000-015-0262-8

25907675

Tsai

Leung

Chen

Chan

Lam

Ger

Arm Selection Preference of MicroRNA-193a Varies in Breast Cancer

Sci Rep6281762016

10.1038/srep28176

27307030

Figure 1.

Validation of miR-193a-3p expression in different databases. (A) TCGA, (B) GSE40807, (C) GSE73182, (D) GSE62054 and (E) E-MTAB-736. miR, microRNA; TC, thyroid cancer; TCGA, The Cancer Genome Atlas.

Figure 2.

Receiver operating characteristic curve analysis of miR-193a-3p from TCGA and GEO databases. (A) TCGA, (B) GSE40807, (C) GSE73182, (D) GSE62054 and (E) E-MTAB-736. miR, microRNA; TCGA, The Cancer Genome Atlas; GEO, Gene Expression Omnibus; AUC, area under curve.

Figure 3.

Meta-analysis of miR-193a-3p in TC. (A) Forest plot curve for evaluating miR-193a-3p expression in TC compared with non-cancerous tissues, the pooled SMD was −1.00 [P<0.001; 95% CI, −1.21-(−0.79)]. (B) AUC of sROC Curve was 0.80 (95% CI, 0.76–0.83), which indicated a moderate ability to differentiate TC from non-cancer samples. The pooled sensitivity and specificity were 0.69 (95% CI, 0.59–0.78) and 0.82 (95% CI, 0.67–0.91), respectively. (C) Begg's test. (D) Egger's test. miR, microRNA; TC, thyroid cancer; SMD, standard mean difference; CI, confidence interval; AUC, area under curve; sROC, summary receiver operating characteristic; TCGA, The Cancer Genome Atlas.

Figure 4.

Identification of miR-193a-3p -related target genes. (A) Venn diagram for overlap among GEO, TCGA and miRWalk. (B) Protein-protein interaction network of the target genes. Each node represents a protein. The lines represent the interaction between the proteins. Different line colors correspond to different types of interaction (blue, from curated databases; pink, experimentally determined; yellow, textmining; black, co-expression). GEO, Gene Expression Omnibus; TCGA, The Cancer Genome Atlas.

Figure 5.

Gene Ontology and disease ontology analyses of microRNA-193a-3p target genes. (A) Biological processes. (B) Cellular components. (C) Molecular functions. (D) Disease Ontology terms.

Figure 6.

Upregulation of CCND1 in TC compared to non-cancerous tissues based on different databases. (A) TCGA, (B) GSE3678, (C) GSE6004, (D) GSE9115, (E) GSE27115, (F) GSE29265, (G) GSE33630, (H) GSE35570, (I) GSE50901, (J) GSE53072, (K) GSE53157, (L) GSE58689, (M) GSE65144 and (N) GSE6339. TC, thyroid cancer. CCND1, cyclin D1; TCGA, The Cancer Genome Atlas.

Figure 7.

Receiver operating characteristic curves of CCND1 expression for differentiating thyroid cancer from non-cancerous thyroid tissues. (A) The Cancer Genome Atlas, (B) GSE3678, (C) GSE6004, (D) GSE9115, (E) GSE27115, (F) GSE29265, (G) GSE33630, (H) GSE35570, (I) GSE50901, (J) GSE53072, (K) GSE53157, (L) GSE58689, (M) GSE65144 and (N) GSE6339 datasets. CCND1, cyclin D1; AUC, area under curve.

Figure 8.

Meta-analysis of CCND1 from public databases. (A) Forest plot curve of the meta-analysis for evaluating CCND1 expression between TC and non-cancerous tissues, the merged SMD was 1.83 (P<0.001; 95% CI, 1.41–2.26). (B) sROC of CCND1 in TC from TCGA and GEO databases was 0.91 (95% CI, 0.89–0.94), which demonstrated that CCND1 probably plays crucial role in distinguishing TC from non-cancerous tissues. The pooled sensitivity and specificity at 0.85 (95% CI, 0.81–0.89) and 0.98 (95% CI, 0.90–1.00), respectively. (C) Begg's test. (D) Egger's test. CCND1, cyclin D1; TC, thyroid cancer; SMD, standard mean difference; sROC, summary receiver operating characteristic; TCGA, The Cancer Genome Atlas; GEO, Gene Expression Omnibus.

Figure 9.

Dual luciferase assay. (A) miR-193a-3p binding site in the 3′ UTR region of CCND1. (B) After co-transfection into 293 cells, miR-193a-3p reduced the luciferase activity of the CCND1 3′ UTR (P<0.05). TRAF6 3′ UTR + mimic-NC and TRAF6 3′ UTR + miR-146 were used as positive control. The x-axis represented the relative fluorescence value. The y-axis represented different test groups. *P<0.05. Expression of (C) miR-193a-3p and (D) miR-146 in 293 cells following transfection with mimic. **P<0.01, ***P<0.001 vs. mimic control. (E) Pearson's correlation analysis between miR-193a-3p expression levels and CCND1 levels from TCGA (r=−0.163). miR, microRNA. miR, microRNA; CCND1, cyclin D1; TNFR6, tumor necrosis factor receptor associated factor 6; UTR, untranslated region; Wt, wild-type; Mut, mutant; NC, negative control.

Figure 10.

Immunohistochemical staining for CCND1 in thyroid cancer tissues from The Human Protein Atlas. (A and B) CCND1 expression was clearly observed in follicular adenoma carcinoma tissues (version 19.3; http://www.proteinatlas.org/ENSG00000110092-CCND1/pathology/thyroid+cancer#img). (C and D) CCND1 expression was not detected in normal thyroid tissues. Magnification, ×200 (version 19.3; http://www.proteinatlas.org/ENSG00000110092-CCND1/tissue/Thyroid+gland#img). CCND1, cyclin D1.

Table I.

Association between miR-193a-3p expression and clinicopathological variables in TC from The Cancer Genome Atlas.

		miR-193a-3p expression

Clinicopathological feature	Cases	Mean ± SD	t/F value	P-value
Tissue
Non-cancerous tissues	59	3.88±0.73	8.468	<0.001
TC	510	3.00±0.75
Sex
Male	134	2.89±0.73	−2.022	0.044
Female	368	3.04±0.76
Pathologic tumor grade
Stage I–II	334	2.99±0.78	−0.459	0.647
Stage III–IV	166	3.02±0.72
Age
<60	383	3.04±0.75	2.336	0.020
≥60	119	2.86±0.77
TNM stage
T1-T2	310	3.01±0.77	0.433	0.665
T3-T4	190	2.98±0.74
Pathological lymph node
No	229	2.96±0.75	−1.074	0.283
Yes	223	3.04±0.73
Metastasis
No	278	3.03±0.76	1.990	0.048
Yes	9	2.52±0.95
Ethnicity
Caucasian	330	3.00±0.77	2.236	0.108
African-American	27	2.69±0.73
Asian	52	3.01±0.68

miR, microRNA; TC, thyroid cancer.

Table II.

General characteristics of included microarray and RNA sequencing datasets.

Authors, year	Country	Dataset	Cancer group	Non-cancer groups	Refs.
TCGA, 2018	USA	TCGA	510	59	–
Lassalle et al, 2016	France	GSE40807	40	40	(42)
Stokowy et al, 2014	Norway	GSE62054	17	5	Unpublished data
Minna et al, 2016	Italy	GSE73182	19	5	(43)
Rossing et al, 2012	Denmark	E-MTAB-736	12	22	(44)

TCGA, The Cancer Genome Atlas.

Table III.

Enrichment GO and disease ontology terms of the target genes of microRNA-193a-3p.

A, Biological processes

ID	Term	Count	P-value
GO:0031667	Response to nutrient levels	6	5.58×10⁻⁵
GO:0071900	Regulation of protein serine/threonine kinase activity	6	6.50×10⁻⁵
GO:0009991	Response to extracellular stimulus	6	8.06×10⁻⁵

B, Cellular component

ID	Term	Count	P-value

GO:0042599	Lamellar body	2	2.91×10⁻⁴
GO:0005771	Multivesicular body	2	1.71×10⁻³
GO:0045178	Basal part of cell	2	2.06×10⁻³

C, Molecular function

ID	Term	Count	P-value

GO:1901681	Sulfur compound binding	4	3.34×10⁻⁴
GO:0008201	Heparin binding	3	1.46×10⁻³
GO:0098631	Cell adhesion mediator activity	2	1.87×10⁻³

D, DO terms

ID	Term	Count	P-value

DOID:0060084	Cell type benign neoplasm	10	2.79×10⁻⁷
DOID:1575	Rheumatic disease	6	1.12×10⁻⁵
DOID:418	Systemic scleroderma	6	1.12×10⁻⁵

GO, Gene Ontology; DO, Disease Ontology.

Table IV.

General characteristics of included microarray and RNA sequencing datasets.

Authors, year	Country	Dataset	Cancer group	Non-cancer groups	Refs.
TCGA, 2018	USA	TCGA	513	59	–
Reyes et al, 2005	USA	GSE3678	7	7	Unpublished data
Vasko et al, 2007	USA	GSE6004	14	4	(57)
Fontaine et al, 2008	France	GSE6339	20	122	(58)
Salvatore et al, 2007	USA	GSE9115	15	4	(59)
Giordano et al, 2006	USA	GSE27155	78	21	(60)
Tomas et al, 2011	Belgium	GSE29265	29	20	Unpublished data
Dom et al, 2012	Belgium	GSE33630	60	45	(61)
Handkiewicz-Junak et al, 2016	Poland	GSE35570	32	51	(62)
Barros-Filho et al, 2015	Brazil	GSE50901	61	4	(63)
Pita et al, 2014	Portugal	GSE53072	5	4	(64)
Pita et al, 2009	Portugal	GSE53157	24	3	(65)
Rusinek et al, 2015	Poland	GSE58689	27	18	(66)
von Roemeling et al, 2015	USA	GSE65144	12	13	(67)

TCGA, The Cancer Genome Atlas.

Table V.

Clinical parameters and CCND1 expression in TC from The Cancer Genome Atlas.

		CCND1 expression

Clinicopathological feature	Cases	Mean ± SD	t/F value	P-value
Tissue
Non-cancerous tissues	59	11.66±0.49	−23.800	<0.001
TC	513	13.36±0.74
Sex
Male	136	13.33±0.80	−0.574	0.566
Female	369	13.37±0.72
Pathologic tumor grade
Stage I–II	336	13.33±0.77	−1.269	0.205
Stage III–IV	167	13.42±0.68
Age
<60	385	13.38±0.73	1.114	0.266
≥60	120	13.30±0.78
TNM stage
T1-T2	309	13.33±0.74	−1.148	0.251
T3-T4	194	13.41±0.74
Pathological lymph node
No	230	13.32±0.84	−1.849	0.065
Yes	225	13.44±0.55
Metastasis
No	282	13.40±0.63	−0.662	0.508
Yes	9	13.55±0.71
Ethnicity
Caucasian	334	13.38±0.69	1.278	0.280
African-American	27	13.58±0.43
Asian	51	13.45±0.73

CCND1, cyclin D1; TC, thyroid cancer.